title: Can emerging drug classes improve R&D productivity?
authors.forename: Christoph
authors.initials: C
authors.lastname: Meier
authors.forename: Sarah
authors.initials: S
authors.lastname: Cairns-Smith
authors.forename: Ulrik
authors.initials: U
authors.lastname: Schulze
mesh_terms: D000818:Animals; D035843:Biomedical Research / Q000191:economics / Q000458:organization & administration*; D003362:Cost-Benefit Analysis; D004059:Diffusion of Innovation; D055808:Drug Discovery / Q000191:economics / Q000458:organization & administration*; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D004526:Efficiency; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology; D058990:Molecular Targeted Therapy; D009937:Organizational Objectives; D010600:Pharmacology / Q000191:economics / Q000458:organization & administration*; D011485:Protein Binding
chemical_list: D018796:Immunoconjugates